Increase of Serum Ferritin Levels During HCV Triple Therapy With Telaprevir, PEG-Interferon ALPHA-2A and Ribavirin Predicts Rrvr

被引：0
|
作者：
Zopf, Steffen
Janisch, Florian
Siebler, Juergen
Neurath, Markus F.
Janisch, Hans-Dieter
机构：
来源：
GASTROENTEROLOGY | 2013年 / 144卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
下载
收藏
页码：S980 / S980
页数：1
相关论文
共 50 条
  • [21] Treatment of chronic hepatitis C with PEG-interferon alpha-2b and ribavirin:: 24 weeks of therapy are sufficient for HCV genotype 2 and 3
    Cornberg, M
    Hüppe, D
    Wiegand, J
    Felten, G
    Wedemeyer, H
    Manns, MP
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2003, 41 (06): : 517 - 522
  • [22] Individualized treatment with combination of Peg-interferon alpha 2b and ribavirin in patients infected with HCV genotype 3
    Mangia, Alessandra
    Bandiera, Franco
    Montalto, Giuseppe
    Mottola, Leonardo
    Piazzolla, Valeria
    Minerva, Nicola
    Pellicelli, Adriano
    Ricci, Giovanni L.
    Cela, Marina
    Carretta, Vito
    Scotto, Gaetano
    Bacca, Donato
    Annicchiarico, Brigida
    Romano, Mario
    Russello, Maurizio
    Barbarini, Giorgio
    Agostinacchio, Ernesto
    Andriulli, Angelo
    JOURNAL OF HEPATOLOGY, 2010, 53 (06) : 1000 - 1005
  • [23] Boceprevir (BOC) and Telaprevir (TPV) therapeutic drug monitoring in HCV and HIV-HCV infected patients treated with triple therapy Ribavirine/Peg-interferon/Boceprevir or Telaprevir: impact of the antiretroviral (ARV) treatment
    AS Chantry
    M Tching-Sin
    C Dhiver
    T Allegre
    JM Ruiz
    A Assi
    D Botta-Fridlund
    P Halfon
    O Faucher-Zaegel
    C Solas
    BMC Infectious Diseases, 14 (Suppl 2)
  • [24] Kinetic analysis of insulin resistance and serum adipocytokines levels during peginterferon alpha-2a plus ribavirin therapy in non-diabetic HCV patients
    Venezia, G.
    Lo Iacono, O.
    Petta, S.
    Almasio, P. L.
    Mineo, C.
    Amato, M.
    Mattina, A.
    Di Marco, V.
    De Lisi, S.
    Licata, A.
    Ferraro, D.
    Craxi, A.
    JOURNAL OF HEPATOLOGY, 2006, 44 : S228 - S228
  • [25] Serum HCV RNA kinetics during combination therapy with daily interferon alpha and ribavirin.
    Rothstein, K
    Suvannasankha, A
    DiGregorio, K
    Gross, F
    Peikin, S
    Mushnick, A
    DeAngelo, C
    Salowe, D
    Siegel, H
    Shaw, E
    Bond, K
    Manzarbeitia, C
    Reich, D
    Munoz, S
    HEPATOLOGY, 1998, 28 (04) : 706A - 706A
  • [26] MIXED TREATMENT COMPARISONS TO COMPARE SIMEPREVIR WITH BOCEPREVIR AND TELAPREVIR IN COMBINATION WITH PEG-INTERFERON ALPHA AND RIBAVIRIN (PR) IN PATIENTS INFECTED WITH GENOTYPE 1 HEPATITIS C VIRUS (HCV)
    Taieb, V
    Pacou, M.
    Van Sanden, S.
    Sbarigia, U.
    Mehnert, A.
    Duchesne, I
    VALUE IN HEALTH, 2014, 17 (07) : A665 - A665
  • [27] Rescue therapy with optimized peg-interferon plus ribavirin in HIV/HCV coinfected patients: Critical role of ribavirin plasma levels in the pilot-nr trial
    Labarga, P.
    Vispo, M. E.
    Barreiro, P.
    Garcia-Samaniego, J.
    Rodriguez-Novoa, S.
    Morello, J.
    Pinilla, J.
    Martin-Carbonero, L.
    Troya, J.
    Gonzalez-Lahoz, J.
    Soriano, V.
    JOURNAL OF HEPATOLOGY, 2008, 48 : S299 - S299
  • [28] IL28B BUT NOT ITPA POLYMORPHISM IS ASSOCIATED WITH RESPONSE TO PEG-INTERFERON, RIBAVIRIN AND TELAPREVIR TRIPLE THERAPY IN PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 1
    Hayes, C. Nelson
    Abe, Hiromi
    Miki, Daiki
    Ochi, Hidenori
    Karino, Yoshiyasu
    Toyota, Joji
    Sezaki, Hitomi
    Kobayashi, Mariko
    Akuta, Norio
    Suzuki, Fumitaka
    Kumada, Hiromitsu
    Chayama, Kazuaki
    HEPATOLOGY, 2011, 54 : 832A - 832A
  • [29] A 3-arm randomized study evaluating the efficacy of triple therapy of pegylated or recombinant interferon alpha-2a 3 mu both combined with ribavirin and amantadine versus dual therapy of recombinant interferon alpha-2a plus ribavirin in naive patients with chronic HCV hepatitis
    Mangia, A
    Ricci, G
    Minerva, N
    Persico, M
    Carretta, V
    Bacca, D
    Vinelli, F
    Sogari, G
    Guadagnino, V
    Maio, G
    Andriulli, A
    JOURNAL OF HEPATOLOGY, 2002, 36 : 117 - 117
  • [30] Serum 25(OH)D3 levels affect treatment outcomes for telaprevir/peg-interferon/ribavirin combination therapy in genotype 1b chronic hepatitis C
    Atsukawa, Masanori
    Tsubota, Akihito
    Shimada, Noritomo
    Abe, Hiroshi
    Kondo, Chisa
    Itokawa, Norio
    Nakagawa, Ai
    Iwakiri, Katsuhiko
    Kawamoto, Chiaki
    Aizawa, Yoshio
    Sakamoto, Choitsu
    DIGESTIVE AND LIVER DISEASE, 2014, 46 (08) : 738 - 743
12345